Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
about
Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systemsTandem laser-induced fluorescence and mass spectrometry detection for high-performance liquid chromatography analysis of the in vitro metabolism of doxorubicin.Urinary biomarkers of oxidative status in a clinical model of oxidative assaultAssessment of the validity of a population pharmacokinetic model for epirubicin.Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry testsA monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.The differential effects of green tea on dose-dependent doxorubicin toxicity.Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin.A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration.Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy.Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus.Effects of anticancer agents and scavengers on CMV-promoter-driven exogenous gene expression in genetically modified cells.Regulation of CMV promoter-driven exogenous gene expression with doxorubicin in genetically modified cells.A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors.The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactionsPrediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues.Mechanistically elucidating the in vitro safety and efficacy of a novel doxorubicin derivative.Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer.Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride.Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.DOX-Vit D, a Novel Doxorubicin Delivery Approach, Inhibits Human Osteosarcoma Cell Proliferation by Inducing Apoptosis While Inhibiting Akt and mTOR Signaling Pathways
P2860
Q27025606-4B0685B5-7C2E-449D-BA81-936BE57DC8ECQ33687552-57A4FD61-A934-42CD-A0B6-12C0B12E7EBEQ33903116-F4051E34-F0DD-44DC-AD26-FC0D0ABDA9C1Q35827620-44965F61-CC77-4CC7-AACC-04F9CC15B377Q35993120-4DDA77A4-9F17-4978-B2F6-641A3153D567Q35994452-09C53CD5-0301-4449-B959-212633E03D36Q36398643-00BC0064-50D5-47BB-B3F2-CEE7616AB06CQ36591937-2783EC3F-E564-436B-ADC5-45FA9727637CQ36617222-5B9301DA-1571-4D5A-8EC1-974D1FBD9630Q36696233-DB38BB36-D633-4EFF-9DDC-1364D1840C52Q37124125-F24C50A9-712D-49A9-924B-712747CB1865Q37276961-5B6C10FD-DB35-495F-A0CF-C6AC3C43F4D0Q38836010-90DE6C05-7190-409C-8679-63FAA5468693Q39596127-D7A388D9-DF7A-422E-98C9-D445B1E5183AQ39870878-614DE9EF-C6D4-4689-B1D4-00F753FA6D27Q39919091-001BD097-A12E-49F8-B152-DB09D26A5DA9Q40375402-17EE6E31-6C49-4A46-B565-B3ED02B8F9CFQ41030442-8736B7C9-9862-4519-B525-42740DA4AB9CQ43844067-5F9D6573-69B1-4BC4-BC1F-878C3E5B9BA2Q46373476-71A32A5D-3377-43C4-8E4A-DBBFCE91207CQ46830250-EEE2948C-254B-4C28-AE98-451C4B7C8DB9Q46897799-AE059B94-809D-49A0-BD8D-80BA433E41D2Q55234480-A8CEA335-8329-4F37-A895-B8C65D7D3E78Q58764297-DAE7877B-2BCE-4B28-91DC-BC72DE203EBA
P2860
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
1988年论文
@zh
1988年论文
@zh-cn
name
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
@en
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
@nl
type
label
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
@en
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
@nl
prefLabel
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
@en
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
@nl
P2093
P356
P1476
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
@en
P2093
P304
P356
10.1200/JCO.1988.6.3.517
P407
P577
1988-03-01T00:00:00Z